1. Home
  2. RNAC vs HEQ Comparison

RNAC vs HEQ Comparison

Compare RNAC & HEQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cartesian Therapeutics Inc.

RNAC

Cartesian Therapeutics Inc.

HOLD

Current Price

$5.80

Market Cap

161.2M

Sector

Health Care

ML Signal

HOLD

Logo John Hancock Hedged Equity & Income Fund of Beneficial Interest

HEQ

John Hancock Hedged Equity & Income Fund of Beneficial Interest

HOLD

Current Price

$10.53

Market Cap

130.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNAC
HEQ
Founded
2007
N/A
Country
United States
United States
Employees
75
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
161.2M
130.0M
IPO Year
2016
2010

Fundamental Metrics

Financial Performance
Metric
RNAC
HEQ
Price
$5.80
$10.53
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$35.00
N/A
AVG Volume (30 Days)
174.9K
50.4K
Earning Date
03-09-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,797,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.98
$9.23
52 Week High
$14.56
$11.58

Technical Indicators

Market Signals
Indicator
RNAC
HEQ
Relative Strength Index (RSI) 36.12 32.84
Support Level N/A N/A
Resistance Level $8.10 $10.80
Average True Range (ATR) 0.56 0.18
MACD -0.19 -0.04
Stochastic Oscillator 5.57 1.20

Price Performance

Historical Comparison
RNAC
HEQ

About RNAC Cartesian Therapeutics Inc.

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.

About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest

John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return, with a focus on current income and gains, and to include long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.

Share on Social Networks: